158 related articles for article (PubMed ID: 15007269)
41. 12 years' experience with intraoperative radiotherapy (IORT) of malignant gliomas.
Schueller P; Micke O; Palkovic S; Schroeder J; Moustakis C; Bruns F; Schuck A; Wassmann H; Willich N
Strahlenther Onkol; 2005 Aug; 181(8):500-6. PubMed ID: 16044217
[TBL] [Abstract][Full Text] [Related]
42. MiRNA expression profiling in human gliomas: upregulated miR-363 increases cell survival and proliferation.
Conti A; Romeo SG; Cama A; La Torre D; Barresi V; Pezzino G; Tomasello C; Cardali S; Angileri FF; Polito F; Ferlazzo G; Di Giorgio R; Germanò A; Aguennouz M
Tumour Biol; 2016 Oct; 37(10):14035-14048. PubMed ID: 27495233
[TBL] [Abstract][Full Text] [Related]
43. [Occurrence and molecular pathology of low grade gliomas].
Murnyák B; Csonka T; Klekner A; Hortobágyi T
Ideggyogy Sz; 2013 Sep; 66(9-10):305-11. PubMed ID: 24358685
[TBL] [Abstract][Full Text] [Related]
44. Association between laminin-8 and glial tumor grade, recurrence, and patient survival.
Ljubimova JY; Fugita M; Khazenzon NM; Das A; Pikul BB; Newman D; Sekiguchi K; Sorokin LM; Sasaki T; Black KL
Cancer; 2004 Aug; 101(3):604-12. PubMed ID: 15274074
[TBL] [Abstract][Full Text] [Related]
45. Glioma models.
Dai C; Holland EC
Biochim Biophys Acta; 2001 Aug; 1551(1):M19-27. PubMed ID: 11553418
[TBL] [Abstract][Full Text] [Related]
46. Radiation therapy of primary tumors.
Sheline GE
Semin Oncol; 1975 Mar; 2(1):29-42. PubMed ID: 188200
[No Abstract] [Full Text] [Related]
47. A tiger behind many doors: multiple genetic pathways to malignant glioma.
Louis DN; Gusella JF
Trends Genet; 1995 Oct; 11(10):412-5. PubMed ID: 7482768
[TBL] [Abstract][Full Text] [Related]
48. [Pathologic anatomy of diffuse gliomas in the adult].
Rousseau A
Soins; 2009 Mar; (733):28-9. PubMed ID: 19365996
[No Abstract] [Full Text] [Related]
49. [Prognostic factors in malignant gliomas].
Ushio Y; Kochi M
Gan To Kagaku Ryoho; 1996 Apr; 23(5):643-8. PubMed ID: 8678527
[TBL] [Abstract][Full Text] [Related]
50. SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas.
Zhang YA; Zhou Y; Luo X; Song K; Ma X; Sathe A; Girard L; Xiao G; Gazdar AF
EBioMedicine; 2016 Nov; 13():80-89. PubMed ID: 27840009
[TBL] [Abstract][Full Text] [Related]
51. [Current classification of gliomas].
Taillibert S; Pedretti M; Sanson M
Presse Med; 2004 Oct; 33(18):1274-7. PubMed ID: 15611709
[TBL] [Abstract][Full Text] [Related]
52. Clinicopathological features in the recurrence of oligodendroglioma and diffuse astrocytoma.
Takeuchi H; Hosoda T; Kitai R; Kodera T; Arishima H; Tsunetoshi K; Neishi H; Yamauchi T; Sato K; Imamura Y; Itoh H; Kubota T; Kikuta K
Brain Tumor Pathol; 2012 Jul; 29(3):140-7. PubMed ID: 22648019
[TBL] [Abstract][Full Text] [Related]
53. Long-term passage results of glioma cells and their cell kinetics.
Matsumura K; Kawamoto K
Hum Cell; 1994 Sep; 7(3):158-66. PubMed ID: 7873500
[TBL] [Abstract][Full Text] [Related]
54. Favorable prognosis in patients with high-grade glioma with radiation necrosis: the University of Colorado reoperation series.
Rusthoven KE; Olsen C; Franklin W; Kleinschmidt-DeMasters BK; Kavanagh BD; Gaspar LE; Lillehei K; Waziri A; Damek DM; Chen C
Int J Radiat Oncol Biol Phys; 2011 Sep; 81(1):211-7. PubMed ID: 20732762
[TBL] [Abstract][Full Text] [Related]
55. Preoperative anaplastic glioma tumor volume effects on patient survival.
Xue D; Albright RE
J Surg Oncol; 1999 Dec; 72(4):199-205. PubMed ID: 10589034
[TBL] [Abstract][Full Text] [Related]
56. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.
Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ
Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864
[TBL] [Abstract][Full Text] [Related]
57. Histone H1.0--a potential molecular marker with prognostic value for patients with malignant gliomas.
Gabrovsky N; Georgieva M; Laleva M; Uzunov K; Miloshev G
Acta Neurochir (Wien); 2013 Aug; 155(8):1437-42. PubMed ID: 23812966
[TBL] [Abstract][Full Text] [Related]
58. Molecular pathways in the formation of gliomas.
von Deimling A; Louis DN; Wiestler OD
Glia; 1995 Nov; 15(3):328-38. PubMed ID: 8586467
[TBL] [Abstract][Full Text] [Related]
59. Impact of Resection on Survival of Isocitrate Dehydrogenase 1-Mutated World Health Organization Grade II Astrocytoma After Malignant Progression.
Grau SJ; Hampl JA; Kohl AC; Timmer M; Duval IV; Blau T; Ruge MI; Goldbrunner RH
World Neurosurg; 2017 Jul; 103():180-185. PubMed ID: 28377251
[TBL] [Abstract][Full Text] [Related]
60. BAC array CGH distinguishes mutually exclusive alterations that define clinicogenetic subtypes of gliomas.
Idbaih A; Marie Y; Lucchesi C; Pierron G; Manié E; Raynal V; Mosseri V; Hoang-Xuan K; Kujas M; Brito I; Mokhtari K; Sanson M; Barillot E; Aurias A; Delattre JY; Delattre O
Int J Cancer; 2008 Apr; 122(8):1778-86. PubMed ID: 18076069
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
